Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00136084 · OUTCOME

Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia · Source last updated 2012-12-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Participants
Interval / dispersion
Not reported
Time frame
Induction II

What was measured

To estimate proportion of patients with MRD reduction after one course of Induction II (cytarabine + daunomycin + etoposide (ADE) + GO), who had no response to first course of induction therapy.

Analysis population: Out of the 30 patients received ADE + GO treatment, one patient had inevaluable MRD prior to and after the treatment. 29 patients were analyzed. Out of the 29 patients, 10 patients were treated on HDAC arm and 19 patients were treated on LDAC arm.

Groups in this outcome

Overall

Patients who have no response to one course of induction therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Overall29

Reported measurements

Decrease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Overall27Not reportedNot reportedNot reportedNot reported
Increase or no change
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Overall2Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    .772
    ci Pct Value
    95
    ci Upper Limit
    .992
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    param Type
    Binomial proportion
    param Value
    .931
    statistical Method
    Binomial proportion
    tested Non Inferiority
    false
Complete source fields
analyses
  1. ci Lower Limit
    .772
    ci Pct Value
    95
    ci Upper Limit
    .992
    group Ids
    1. OG000
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    param Type
    Binomial proportion
    param Value
    .931
    statistical Method
    Binomial proportion
    tested Non Inferiority
    false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        27
    title
    Decrease
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Increase or no change
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    units
    Participants
description
To estimate proportion of patients with MRD reduction after one course of Induction II (cytarabine + daunomycin + etoposide (ADE) + GO), who had no response to first course of induction therapy.
groups
  1. description
    Patients who have no response to one course of induction therapy
    id
    OG000
    title
    Overall
param Type
NUMBER
population Description
Out of the 30 patients received ADE + GO treatment, one patient had inevaluable MRD prior to and after the treatment. 29 patients were analyzed. Out of the 29 patients, 10 patients were treated on HDAC arm and 19 patients were treated on LDAC arm.
reporting Status
POSTED
time Frame
Induction II
title
Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice